In the present study, we aim to: (1) identify vulnerable hippocampal neurons affected by tau pathology in AD; (2) uncover the molecular mechanisms underlying this vulnerability; and (3) evaluate the effectiveness of DEPTAC in improving vulnerable hippocampal neurons in the presence of tau pathology. This evidence concerns the gene MAPT and Alzheimer disease.